Member Login

Can we move closer to a functional cure for chronic hepatitis B?

5 June

A major phase 3 trial published in the New England Journal of Medicine found that bepirovirsen, an antisense oligonucleotide targeting hepatitis B virus RNA, helped more patients achieve a functional cure compared with placebo after stopping nucleos(t)ide analogue therapy. While adverse events were more common, the findings represent an important advance in the search for curative therapies for the nearly 300 million people living with chronic hepatitis B worldwide.

#HepatitisB #InfectiousDiseases #LiverHealth #HBV #ASID #ClinicalResearch

Inge Meggitt

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES
ABN 20 108 151 093
ACN 155 632 698
PO BOX Q379 QVB SYDNEY 1230
ADMIN@asid.net.au

ASID acknowledges the Aboriginal and Torres Strait Islander peoples as Traditional Owners, Custodians and First Nations of Australia, and Māori as tangata whenua and Treaty of Waitangi partners in Aotearoa New Zealand.

Can we move closer to a functional cure for chronic hepatitis B?

Position Statement on Planetary Health